Based in New Jersey, Becton, Dickinson and Company (BDX – Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Currently, Becton, Dickinson has a Zacks Rank #3 (Hold) but that could change following its first-quarter fiscal 2017 earnings report which has just released.

Earnings: 

Becton, Dickinson’s adjusted earnings of $2.33 per share beat the Zacks Consensus Estimate by 22 cents and increased from $1.96 posted in the year-ago quarter on a currency-neutral basis.

Becton, Dickinson and Company Price and EPS Surprise

Becton, Dickinson and Company Price and EPS Surprise | Becton, Dickinson and Company Quote

Revenues: Adjusted revenues amounted to $2.92 billion, down 2.1% from the year-ago quarter on a comparable currency-neutral basis. Revenues beat the Zacks Consensus Estimate of $2.85 billion.

Key Stats: BD Medical generated revenues of $1.96 billion, down 4.4% on a year-over-year basis. BD Lifesciences generated revenues of $958 million, up 2.7% from the year-ago quarter. On a comparable basis, adjusted U.S. revenues increased 5.5%. International revenues increased 6.8% on a currency-neutral basis in the reported quarter.

Major Factors: BD Medical’s year over year growth reflects strong performance in the Pharmaceutical Systems and Medication Management Solutions units. Revenue growth in the BD Lifesciences segment reflects strong performance in the Diagnostic Systems and Preanalytical Systems units.

Print Friendly, PDF & Email

Related Posts